RxDoctor Payments Data

Felipe del Valle, MD

Internal Medicine · Miami, FLNPI 1174508717

Payments from drug & device makers

$2,177in general payments, 2019–2025

Across 53 payments — averaging $41.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$435
  • Biotronik Inc.$367
  • Johnson & Johnson$344
  • Medtronic$333
  • AstraZeneca$141
  • Lilly USA, LLC$126
  • plus $431 from 11 others

What the payments were for

  • Food & beverage$2,177100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,177 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$42,397
Medicare patients
143
Services billed
499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban456$408,079
FarxigaDapagliflozin Propanediol123$94,181
JardianceEmpagliflozin87$88,714
XareltoRivaroxaban86$84,748
EntrestoSacubitril/Valsartan66$63,614
OzempicSemaglutide57$60,488
TradjentaLinagliptin51$54,604
JanuviaSitagliptin Phosphate35$35,266
DescovyEmtricitabine/Tenofov Alafenam13$32,641
RestasisCyclosporine35$30,231
MounjaroTirzepatide22$26,778
MyrbetriqMirabegron40$23,967
Tresiba Flextouch U-100Insulin Degludec43$18,490
MultaqDronedarone Hcl19$16,704
SynthroidLevothyroxine Sodium145$14,432

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$60$408,079456 claims
Boehringer IngelheimJardiance, Tradjenta, Glyxambi$50$157,085155 claims
AstraZenecaFarxiga, Brilinta$141$100,007134 claims
Johnson & JohnsonXarelto$344$84,74886 claims
Novo NordiskOzempic, Rybelsus$44$71,08969 claims
NovartisEntresto$50$63,61466 claims
Lilly USA, LLCMounjaro$126$26,77822 claims
GSKTrelegy Ellipta, Anoro Ellipta$25$17,00931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →